Cargando…
Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases.
Hepatic arterial floxuridine (HAI) in 35 patients with systemic fluorouracil/folinic acid-resistant colorectal liver metastases achieved a 14% partial response and 26% disease stabilization rate, with a median response duration of 7 months from onset of HAI.
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group|1
1998
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063159/ https://www.ncbi.nlm.nih.gov/pubmed/9792150 |
| _version_ | 1782137279364464640 |
|---|---|
| author | Fordy, C. Glover, C. Davies, M. M. Allen-Mersh, T. G. |
| author_facet | Fordy, C. Glover, C. Davies, M. M. Allen-Mersh, T. G. |
| author_sort | Fordy, C. |
| collection | PubMed |
| description | Hepatic arterial floxuridine (HAI) in 35 patients with systemic fluorouracil/folinic acid-resistant colorectal liver metastases achieved a 14% partial response and 26% disease stabilization rate, with a median response duration of 7 months from onset of HAI. |
| format | Text |
| id | pubmed-2063159 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 1998 |
| publisher | Nature Publishing Group|1 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-20631592009-09-10 Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. Fordy, C. Glover, C. Davies, M. M. Allen-Mersh, T. G. Br J Cancer Research Article Hepatic arterial floxuridine (HAI) in 35 patients with systemic fluorouracil/folinic acid-resistant colorectal liver metastases achieved a 14% partial response and 26% disease stabilization rate, with a median response duration of 7 months from onset of HAI. Nature Publishing Group|1 1998-10 /pmc/articles/PMC2063159/ /pubmed/9792150 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Research Article Fordy, C. Glover, C. Davies, M. M. Allen-Mersh, T. G. Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. |
| title | Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. |
| title_full | Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. |
| title_fullStr | Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. |
| title_full_unstemmed | Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. |
| title_short | Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. |
| title_sort | hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. |
| topic | Research Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063159/ https://www.ncbi.nlm.nih.gov/pubmed/9792150 |
| work_keys_str_mv | AT fordyc hepaticarterialfloxuridineassecondlinetreatmentforsystemicfluorouracilresistantcolorectallivermetastases AT gloverc hepaticarterialfloxuridineassecondlinetreatmentforsystemicfluorouracilresistantcolorectallivermetastases AT daviesmm hepaticarterialfloxuridineassecondlinetreatmentforsystemicfluorouracilresistantcolorectallivermetastases AT allenmershtg hepaticarterialfloxuridineassecondlinetreatmentforsystemicfluorouracilresistantcolorectallivermetastases |